← Back to Search

Unknown

AMZ002 injectable solution, 0.5mg/mL for Infantile Spasms

Phase 3
Waitlist Available
Research Sponsored by Amzell
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing a new treatment called AMZ002 to see if it works better than Vigabatrin for babies who have just been diagnosed with infantile spasms. The goal is to find out which treatment can better control or reduce their seizures. Vigabatrin has been used as a treatment for infantile spasms and is considered effective, often compared with hormonal treatments like ACTH.

Eligible Conditions
  • Infantile Spasms

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: AMZ002Experimental Treatment1 Intervention
Group II: VigabatrinActive Control1 Intervention

Find a Location

Who is running the clinical trial?

AmzellLead Sponsor
2 Previous Clinical Trials
518 Total Patients Enrolled
~0 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top